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a b s t r a c t
To avoid legislation based on chemical structure, research chemicals, frequently used for recreational
purposes, are continually being synthesized. N-Ethyl-1,2-diphenylethanamine (ephenidine) is a diary-
lethylamine that has recently become popular with recreational users searching for dissociative hallu-
cinogenic effects.
In the present study, the pharmacological basis of its neural actions has been investigated, initially by
assessing its proﬁle in central nervous system receptor binding assays and subsequently in targeted
electrophysiological studies. Ephenidine was a potent inhibitor of 3H-MK-801 binding (Ki: 66 nM),
implying that it acts at the PCP site of the N-methyl-D-aspartate (NMDA) receptor. It also showed modest
activity at dopamine (379 nM) and noradrenaline (841 nM) transporters and at sigma 1 (629 nM) and
sigma 2 (722 nM) binding sites. In experiments of extracellular recording of ﬁeld excitatory postsynaptic
potentials (fEPSPs) from area CA1 of rat hippocampal slices, ephenidine, 1 and 10 mM, respectively,
produced a 25% and a near maximal inhibition of the NMDA receptor mediated fEPSP after 4 h super-
fusion. By contrast, ephenidine (50 mM) did not affect the AMPA receptor mediated fEPSPs. In whole cell
patch clamp recordings, from hippocampal pyramidal cells, ephenidine (10 mM) blocked NMDA receptor-
mediated EPSCs in a highly voltage-dependent manner. Additionally, ephenidine, 10 mM, blocked the
induction of long term potentiation (LTP) in CA1 induced by theta burst stimulation.
The present data show that the new psychoactive substance, ephenidine, is a selective NMDA receptor
antagonist with a voltage-dependent proﬁle similar to ketamine. Such properties help explain the
dissociative, cognitive and hallucinogenic effects in man.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Shortly after their development as potential general anesthetics
for veterinary and human use (Greifenstein et al., 1958; McCarthy
et al., 1965; Domino et al., 1965), both phencyclidine (PCP) and
ketamine were widely abused throughout the world for their
dissociative effects (Petersen and Stillman, 1978; Jansen, 2000).
Although PCP is still abused as a ‘street drug’ in the USA, its misuse
has been reduced particularly in Europe because of severe and long
lasting psychotomimetic effects, including lethality (Moeller et al.,
2008) whereas the shorter-acting ketamine has remained a popu-
lar recreational drug (Freese et al., 2002; Nutt et al., 2007; Morris
and Wallach, 2014), although not without dangers (Morgan and
Curran, 2012). However, legislation has been enacted in many
countries in an attempt to prevent their use and sale, which in turn
has resulted in a burgeoning of new chemicals with dissociative
properties (Roth et al., 2013; Morris and Wallach, 2014). Interest-
ingly, the most common structures, like phencyclidine, are tricyclic
Abbreviations: NMDA, N-methyl-D-aspartate; AMPA, a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionate; D-AP5, D-2-amino-5-phosphonopropionate; LTP,
long-term potentiation.
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compounds and include various 1,2-diarylethylamines e.g. diphe-
nidine and 2-methoxydiphenidine (Morris and Wallach, 2014).
Such compounds, although structurally distinct from arylcyclo-
hexylamines, like PCP and ketamine, are well documented in on-
line anecdotal reports, as having potent and long lasting dissocia-
tive effects in man (http://www.bluelight.org/vb/threads/668291-
The-Big-amp-Dandy-Diphenidine-Thread; http://www.erowid.
org/chemicals/methoxphenidine/methoxphenidine_timeline.php;
http://drugs-forum.com/forum/showthread.php?t¼273812). Like
the original dissociative anesthetics (Anis et al., 1983) and other
dissociative hallucinogens (Lodge andMercier, 2015), these tricyclic
1,2-diarylethylamines have proved to be potent and selective
NMDA antagonists (Wallach et al., 2016).
Recently, ephenidine, a two ringed N-ethyl-1,2-
diphenylethylamine, has become available and anecdotally ap-
pears popular with users of dissociative research chemicals e.g.
‘ﬁnally a worthy alternative to ketamine … ’, (http://www.
bluelight.org/vb/threads/766110-The-Big-amp-Dandy-Ephenidine-
%28N-ethyl-1-2-diphenylethylamine%29-Thread; http://www.
psychonaut.com/sintetici/56569-ephenidine.html). An early brief
medicinal chemistry report, without detailing synthesis, suggested
that ephenidine displaced PCP binding (Thurkauf et al., 1989).
However, no suggestion of the relationship to NMDA receptor
antagonism was made nor were its selectivity, its mode of action
and its potential to affect synaptic function and plasticity explored.
We have therefore addressed these and further compared the ef-
fects of ephenidine with those of ketamine on synaptic trans-
mission in hippocampal brain slices using both extracellular and
whole-cell recording techniques. We have also examined the
selectivity of ephenidine by comparing its potency at displacing
MK-801 binding with its actions on a wide range of CNS receptors.
The data show that ephenidine is a relatively selective, voltage-
dependent NMDA antagonist that potently blocks LTP. These ob-
servations can explain the psychotomimetic effects of ephenidine
and predict a range of side-effects including memory impairments.
2. Methods
2.1. Preparation of ephenidine
Full details of the synthesis and analytical characterization of
ephenidine (N-ethyl-1,2-diphenylethylamine) are given in
Supplement 1.
2.2. Receptor binding experiments
The binding afﬁnity (Ki) of ephenidine to the MK-801 binding
site of the NMDA receptor was determined as described by Sharma
and Reynolds (1999). Brieﬂy, after thorough washing of the ho-
mogenate of whole rat brain (Pel-Freez Biologicals), suspensions in
10 mM HEPES (pH 7.4 at room temperature), containing 100 mg/mL
protein, were incubated in the dark on a mechanical rocker for 2 h
in the presence of 1 nM (þ)-[3H]-MK-801, 100 mM glutamate, 10 mM
glycine, and various concentrations of ephenidine, ketamine and
MK-801 or 30 mM (þ)-MK-801 for nonspeciﬁc binding (Sharma and
Reynolds, 1999). Termination of reaction was performed via vac-
uum ﬁltration using a 24 well cell harvester (Brandel, Gaithersburg,
MD) over presoaked GF/B glass ﬁber ﬁlters (Brandel, Gaithersburg,
MD). Filters were washed with room temperature assay buffer
(3  5 mL). Trapped tritium was measured via liquid scintillation
counting, using a Beckman LS 6500 multipurpose scintillation
counter (BeckmanCoulter, USA) at 57% efﬁciency. IC50 values were
determined in Graphpad Prism 5.0 using non-linear regression
with log-concentration plotted against percent speciﬁc binding.
Percent speciﬁc binding for [3H]-MK-801 in control experimentwas
~95% of total. Ki values were calculated using the equation of Cheng
and Prusoff (1973). The Kd for (þ)-MK-801, 1.75 nM, was deter-
mined via homologous binding assay as described by Sharma and
Reynolds (1999) and is consistent with the literature. Protein con-
centration was determined via the Bradford method using Coo-
massie protein assay reagent (Sigma, USA) with rat albumin (Sigma,
USA) as standard. Experiments were performed in duplicate and
repeated three or four times.
Displacement by ephenidine in binding assays of a further 45
CNS receptors was performed through the National Institute of
Mental Health Psychoactive Drug Screening Program (NIMH PDSP).
Brieﬂy ephenidine, dissolved in DMSO, was subject to a primary
screen at a concentration of 10 mM (see Suppl. 2 for radioligands
used). Compounds exhibiting >50% inhibition were subjected to a
secondary assay at varying concentrations to determine Ki values.
Additional experimental details are available in the NIMH PDSP
protocol book (Roth et al., 2013).
2.3. Electrophysiology in hippocampal slices
Male Wistar and Sprague-Dawley rats (Crl:Wi; Charles River,
UK) aged 3e10 weeks old were killed by dislocation of cervical
vertebrae according to Schedule 1 of the United Kingdom (Scientiﬁc
Procedures) Act of 1986. Brains were rapidly removed and put in
artiﬁcial cerebrospinal ﬂuid (aCSF) consisting of 124 mM NaCl,
26 mM NaHCO3, 3 mM KCl, 1.4 mM NaH2PO4, 1 mM MgSO4, 2 mM
CaCl2, and 10mM D-glucose and continuously oxygenated with 95%
O2 and 5% CO2. Parasagittal brain slices, 400 mm thick, of the hip-
pocampus were removed, stored and placed in a submerged
recording chamber at 28e30 C.
Recordings of extracellular synaptic activity were made (Ceolin
et al., 2012; Volianskis et al., 2013) using a bipolar electrode to
deliver stimuli (0.03 Hz) to the Schaffer collateral pathway to evoke
ﬁeld excitatory postsynaptic potentials (fEPSPs) recorded from a
glassmicroelectrode (3e6MU) in the stratum radiatum of area CA1.
The NMDA receptor-mediated component of the fEPSP (NMDA-
fEPSP) was isolated by adding 3 mM NBQX, 50 mM picrotoxin and
1 mM CGP 55845 to the aCSF, which abolished AMPA and GABA
receptor mediated transmission. In initial experiments after 30 min
of stable control responses, the remaining response was challenged
with 30 mM ephenidine. Using this protocol for isolating NMDA-
fEPSPs (see Fig. 2A), 1 and 10 mM ephenidine or 1 and 10 mM D-2-
amino-5-phosphonopentanoic acid (D-AP5) were added to the
perfusate for up to 4 h while recording the amplitude and area of
the NMDA-fEPSP on-line usingWinLTP (Anderson and Collingridge,
2007). Single exponential curves were ﬁtted to show likely half-
times and minimum plateau responses achieved with each con-
centration used. For selectivity experiments, 50 mM picrotoxin and
1 mM CGP 55845 were added to the solution from the beginning of
the experiment and 50 mM ephenidine was superfused for 60 min
in the absence of other pharmacological agent. Under these con-
ditions the AMPA receptor mediated fEPSP dominates the
recording. 5 mM ephenidine with 3 mM NBQX were then added to
the perfusate for another 1 h to conﬁrm that NMDA-fEPSP had been
abolished.
To study the effect of ephenidine on long-term potentiation
(LTP), slices were incubated in control aCSF or aCSF containing
10 mM ephenidine for at least 2 h before transferring to the
recording chamber, fEPSPs were recorded as above without addi-
tion of other agents. After obtaining stable responses, a theta burst
stimulation (TBS; Park et al., 2016) was applied to the Schaffer
collateral pathway and the amplitude of the fEPSP in CA1 moni-
tored for at least a further 40 min.
Whole-cell patch clamp recordings of excitatory postsynaptic
currents (EPSCs) were made from CA1 pyramidal cells under visual
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guidance with IR-DIC optics as described by Park et al. (2016). The
recording chamber was maintained at 32 C. Borosilicate glass pi-
pettes were usedwith a resistance of 3e5MU. The internal solution
comprised (mM): 8 NaCl, 130 CsMeSO3, 10 HEPES, 0.5 EGTA, 4 Mg-
ATP, 0.3 Na3-GTP, 5 QX-314 and 0.1 spermine. The pH was adjusted
to 7.2e7.3 with CsOH and osmolarity to 285e290 mOsm. Peak
amplitude of EPSCs was measured while varying holding voltage
from 60 mV to þ60 mV and stimulating the Schaffer collateral
pathway at a frequency of 0.1 Hz at constant intensity. Five
consecutive responses obtained at each holding potential were
averaged to plot the current-voltage relationship. Currents through
NMDA receptors were pharmacologically isolated using 10 mM
NBQX, 50 mM picrotoxin and 20 mM (þ)-bicuculline. In initial ex-
periments, MgSO4 was omitted from the bath solution for at least
30min before patching and replaced with 30 mMephenidine,10 mM
ketamine, 30 mMD-AP5 or 2 mMMgSO4. Rectiﬁcation indices were
calculated from the EPSC values at þ40 mV and 40 mV. In sub-
sequent experiments, slices were incubated in aCSF with no added
MgSO4, before transferring to the recording chamber to obtain
control current-voltage plots from NMDA-EPSCs as above before
adding 2 mMMgSO4 or 30 mMephenidine for 30min and repeating
the current-voltage protocol. Representative sample traces are
shown from typical experiments, and stimulus artifacts blanked for
clarity. Data were normalized to the baseline preceding drug
application, and are presented as mean ± SEM and compared using
one-way ANOVA and level of signiﬁcance is denoted as *** for p
values < 0.001.
3. Results
3.1. Receptor binding data
Fig. 1 shows the (þ)-[3H]-MK-801 displacement curves by con-
centrations of ephenidine, ketamine and MK-801 from 0.1 nM to
100 mM. Thus ephenidine showed nanomolar afﬁnity with a
calculated Ki value of 66.4 ± 3.7 nM. This compareswith Ki values in
the same assay for ketamine and MK-801 of 324 ± 19 and
2.1 ± 0.3 nM respectively (Wallach et al., 2016). The parallel nature
of the curves suggests that all three compounds bind to the same
site in the NMDA receptor-channel complex.
The data from the NIMH PDSP assay (Table S1) shows that
ephenidine has submicromolar afﬁnity for the dopamine (379 nM)
and noradrenaline (841 nM) transporters and for sigma 1 (628 nM)
and sigma 2 (721 nM) binding sites. The remaining 41 receptors
evaluated in the binding assays (see Supplement 2) showed less
than 50% displacement with 10 mM ephenidine.
3.2. Electrophysiology in hippocampal slices
In initial experiments, superfusion of hippocampal slices with
NBQX, picrotoxin and CGP55845 containing aCSF to reduce AMPA,
GABA-A and GABA-B receptor-mediated events resulted in fEPSPs,
which were slowly reduced by 30 mM ephenidine (Fig 2A). The
rapid reduction of such fEPSPs in the presence of 1 and 10 mM D-
AP5 (Fig 3A) and slower reduction in presence of 1 and 10 mM ke-
tamine (Fig 3B) conﬁrms their dependence on NMDA receptors. To
investigate further the sensitivity of the fEPSP to ephenidine, in the
presence of the same cocktail of GABA and AMPA receptor antag-
onists, it was superfused at 10 mM, which slowly reduced the fEPSP
reaching a near maximal effect after 4 h. By contrast, the effect of
1 mM ephenidine on this fEPSP was limited to approximate 25%
inhibition after 4 h perfusion (Fig 3C). This slow antagonism by
ephenidine is typical of other use-dependent uncompetitive NMDA
receptor antagonists, e.g. ketamine (Fig 3B) and suggests a similar
mode of action (see Wallach et al., 2016).
To study the selectivity of ephenidine against the AMPA subtype
of glutamate receptor, the effect of ephenidine was studied on the
early component of the fEPSP in the absence of NBQX (Fig 2B). One
hour of superfusionwith 50 mMephenidine produced no signiﬁcant
reduction of the peak amplitude of the fEPSP, although it can be
seen from the individual recordings that the late NMDA receptor-
mediated component is considerably reduced (Fig 2B). Switching
the superfusion to one containing 3 mM NBQX resulted in a rapid
block of the remaining fEPSP (Fig 2B), demonstrating its depen-
dence on AMPA receptors.
To compare the effect of ephenidine on current-voltage rela-
tionship of NMDA receptor mediated synaptic currents, patch
clamp recordings were made in the presence of the above cocktail
of drugs and in the absence of addedMg2þ ions before adding 2mM
Mg2þ (Fig 4A) or 30 mM ephenidine (Fig 4B) to the aCSF for 30 min.
Ephenidine showed a proﬁle typical of a channel blocker, i.e.
reduction of inward current at negative holding potentials. The
rectiﬁcation index (RI), expressed as the ratio of currents at holding
potentials of þ40 mV to 40 mV, was also used to quantify this
proﬁle. In separate studies where slices were bathed in drug-
containing aCSF before patch clamping, RIs were calculated from
similar current-voltage measurements. For example, at 40 mV,
the mean current in 30 mM ephenidine was 48 ± 8 pA and
at þ40 mV was 133 ± 12 pA. The mean of the individual RI values
was 3.6 ± 0.3, which compares with an RI of 0.6 ± 0.01 at the same
holding potentials in control aCSF with no added Mg2þ ions (Fig
4C). Thus, it appears from the RI values (Fig 4C) that 30 mM ephe-
nidine falls between 2 mM Mg2þ (RI ¼ 4.2 ± 0.3) and 10 mM keta-
mine (RI ¼ 2.0 ± 0.2). This is in contrast to the competitive
antagonist, D-AP5, which, as expected, reduced both inward and
outward current, so that its RI (0.8 ± 0.01) remains similar to the
Mg2þ-free control value (Fig 4C).
Other NMDA antagonists block the form of synaptic plasticity
known as long-term potentiation (LTP), although interestingly this
ability varies according to the nature of different channel blockers
Fig. 1. 3H-MK-801 binding experiments. A. Displacement curves showing the
concentration-response relationship of ephenidine, ketamine (data fromWallach et al.,
2016) and MK-801. B. Table showing the calculated IC50 and Ki values for the 3
competing ligands.
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(Frankiewicz et al., 1996). We therefore tested ephenidine in a
standard LTP protocol. Theta burst stimulation (TBS) applied to the
Schaffer collateral pathway provided a robust potentiation of the
fEPSP slope (Fig 5) in control slices interleaved between slices
incubated with 30 (n ¼ 3; data not shown) or 10 mM (n ¼ 5; Fig 5)
ephenidine. At both concentrations, ephenidine completely
blocked the induction of LTP.
4. Discussion
We have shown that ephenidine, an abused psychoactive sub-
stance (Brandt et al., 2014) with dissociative effects in man, is a
relatively selective, potent and voltage-dependent NMDA receptor
antagonist and hence can be classiﬁed as an uncompetitive channel
blocking compound.
Although ephenidine's use was detected in Germany in 2008
(Westphal et al., 2010), its availability from internet retailers has
only been a more recent phenomenon. Ephenidine appears in older
chemical (Goodson et al., 1946) and pharmacological (Tainter et al.,
1943) literature. In a brief medicinal chemistry report, relating it to
MK-801 as an anticonvulsant, its afﬁnity for the PCP binding site
was given as 257 nM (Thurkauf et al., 1989) and information
regarding its rapid metabolism has also recently appeared (Wink
et al., 2014, 2015). However, its ability to affect NMDA receptor
function had not been explored.
The voltage-dependent effects, we report here for ephenidine
(Fig 4), are similar to earlier reports on ketamine (MacDonald et al.,
1987; Davies et al., 1988a,b), memantine and MK-801 (Wong et al.,
Fig. 2. Graphs showing time-course of block of the NMDA receptor-mediated fEPSPs in
CA1 of hippocampal slices by 30 mM ephenidine (A) and lack of effect of ephenidine
50 mM on AMPA receptor-mediated fEPSPs (B). The bars above the graphs indicate the
superfusion times for various compounds. The sample traces at the top show typical
responses at the times indicated by the associated lower case letters below.
Fig. 3. Time-course of inhibition of NMDA receptor-mediated fEPSP by 1 and 10 mM D-
AP5 (A), ketamine (B) and ephenidine (C). In each graph which is the average of 3e5
experiments, a baseline of 30 min was obtained before superfusing the hippocampal
slices with indicated compound. Typical examples of raw data (a, b and c) are taken at
the times indicated on the graphs below.
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1986; Chen et al., 1992; Frankiewicz et al., 1996) and Mg2þ ions
(Nowak et al., 1984; Mayer et al., 1984), in which outward currents
were the less affected. Interestingly the nature of the voltage-
dependency block of NMDA receptors has been related to thera-
peutic potential (Frankiewicz et al., 1996). In the present experi-
ments, due to slowwash-in times of ephenidine, it was not possible
to achieve a full equilibrium block. However, ephenidine is clearly a
highly voltage-dependent blocker of synaptic NMDA receptors and
has a potency slightly greater than ketamine at resting membrane
potentials. When compared with other uncompetitive NMDA an-
tagonists in the same protocol for studying NMDA-fEPSPs (Wallach
et al., 2016), the potency and pharmacodynamic properties of
ephenidine are closer to those of ketamine than of phencyclidine.
Perhaps because of these pharmacodynamic properties or for
some pharmacokinetic reason, ephenidine appears anecdotally to
be popular amongst those interested in the dissociative state (see
Introduction). The subjective effects reported appear dose-
dependent and include dissociative-like effects including mood
and thought alteration and complex visual hallucinations at doses
between 100 and 500 mg (see Introduction).
Many voltage-dependent uncompetitive NMDA antagonists,
such as ketamine, PCP and dextromethorphan, also show
schizophrenia-like effects in man (Lodge and Mercier, 2015).
Although ephenidine is not described as a psychotomimetic agent
in the scientiﬁc literature, anecdotal descriptions of the dissociative
effects of ephenidine (see above) suggest that, in high enough
doses, it mimics some of the symptoms of schizophrenia. Casual
users of ephenidine may put themselves in danger particularly as a
result of the dissociative and analgesic effects of the NMDA receptor
antagonism, as has been similarly described for ketamine abuse
Fig. 4. Whole cell patch clamp recordings of EPSCs from hippocampal pyramidal neurones. A. Current-voltage plots for peak EPSCs before and 30 min after addition of 2 mM Mg2þ
ions to the aCSF as indicated by the coloured symbols (n ¼ 7). B. As for (A) above, no added Mg2þ ions but with the addition of 30 mM ephenidine (n ¼ 6). C. Bar chart showing
rectiﬁcation indices (RI; þ40mV/-40 mV) for EPSCs recorded in aCSF with no added Mg2þ (n ¼ 26; black), 2 mMMg2þ (n ¼ 14; orange), 30 mM D-AP5 (n ¼ 11; blue), 10 mM ketamine
(n ¼ 12; green) or 30 mM ephenidine (n ¼ 21; red). Examples of EPSCs recorded at þ40 mV and 40 mV in the various conditions are shown above each bar graph. (For inter-
pretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 5. Effect of ephenidine on LTP of fEPSPs in the Schaffer collateral CA1 pathway. A.
Examples of the fEPSPs before (a), 5 min after (b) and 40 min after (c) theta burst
stimulation (TBS) of the input to CA1 neurones in the absence (black) or presence (red)
of 10 mM ephenidine. B. Graph showing the mean fEPSP slope values from 5 experi-
ments on hippocampal slices under control conditions and from 5 interleaved exper-
iments on slices incubated in 10 mM ephenidine. TBS is indicated by the arrow at
20 min. (For interpretation of the references to colour in this ﬁgure legend, the reader
is referred to the web version of this article.)
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(Morgan and Curran, 2012). The block of the induction of LTP with
10 mM ephenidine predicts cognitive disruption and amnesia (Bliss
and Collingridge, 1993). Our data also suggests that at even higher
doses, interaction with monoamine transporters and sigma re-
ceptors may contribute to the behavioural effects of ephenidine.
Beside the analgesic and neuroprotective properties of ketamine
(see Lodge and Mercier, 2015), an exciting novel therapeutic target
for ketamine has emerged. Thus, ketamine and some other NMDA
receptor antagonists have recently been proposed as rapidly acting
anti-depressants (Berman et al., 2000; Zarate et al., 2006; Price
et al., 2009). During depressed mood and during stress, memories
of unpleasant events may be established through long-term
potentiation (LTP) and long-term depression (LTD). Treatment
with NMDA receptor antagonists, inhibitors of LTP and LTD, may
block this cycle of pathological plasticity and change mood
(Collingridge et al., 2010). Not all NMDA receptor antagonists have
this property. Thus MK-801, another channel blocker with slower
pharmacodynamic and pharmacokinetic properties than ketamine
(seeWallach et al., 2016), does not show sustained anti-depressant-
like effects (Maeng et al., 2008). It remains to be seen whether
ephenidine, with pharmacodynamic and LTP blocking properties
similar to ketamine, will have the appropriate proﬁle for such a
therapeutic indication.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.neuropharm.2016.08.004.
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